Transforming growth factor a (TGFa) is thought to participate in the normal and pathologic processes of numerous tissues, including the gastric mucosa. To explore its role in vivo, transgenic mice were generated overexpressing TGFa in the stomach. TGFa induced dramatic structural and functional lesions of the glandular stomach that were similar to Menetrier's disease in humans. Transgenic mice developed severe adenomatous hyperplasia that resulted in a striking nodular thickening or hypertrophy of the gastric mucosa. Secretions obtained from affected stomachs contained no detectable gastric acid, suggesting that parietal cell function had been greatly impaired. These findings demonstrate that overproduction of TGFa can stimulate cellular proliferation, suppress acid secretion, and perturb organogenesis ofthe stomach oftransgenic mice. Moreover, TGFa may contribute to the pathogenesis of related human hypertrophic gastropathies, such as Menetrier's disease. (J. Clin. Invest. 1992.90:1161-1167
Introduction
Transforming growth factor a (TGFa)' is a potent mitogen and a member of the epidermal growth factor (EGF) family of peptides (1) (2) (3) (4) (5) . TGFa, which induces biological responses (5) by binding to and activating the tyrosine kinase of the EGF receptor (6) , has been implicated in malignant transformation. Human primary and metastatic tumors often overexpress TGFa (7), and highly active TGFa expression vectors can be transforming when introduced into cultured cells (8) (9) (10) . TGFa and EGF have also been shown to participate in the physiologic function of a multiplicity of tissues (5) , including the mucosa of the stomach, where TGFa and its receptor have been detected in rodents and humans ( 11) . TGFa is a potent 1. Abbreviations used in this paper: EGF, epidermal growth factor; H&E, hematoxylin and eosin; TGFa, transforming growth factor a.
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Transgenic mice have proven to be extremely useful as models for human diseases ( 15 ). We and others have shown that transgenic mice overexpressing TGFa experience a number of phenotypic abnormalities, including neoplasia of the liver and mammary gland (16) (17) (18) (19) . Here, we report that TGFa induces dramatic structural and functional lesions of the transgenic stomach that are reminiscent of Menetrier's disease, a human syndrome that is characterized by a diffuse thickening of the gastric wall caused by extensive hyperplasia of the surface epithelium, and is associated with carcinoma of the stomach (20, 21) .
Methods
Animals. Transgenic mice bearing the metallothionein-TGFa fusion gene were created and identified as described previously ( 16) . Briefly, one-cell mouse embryos from the inbred line FVB/N (Harlan Sprague Dawley, Inc., Indianapolis, IN) were microinjected with an active expression construct containing the mouse metallothionein I gene promoter, the human TGFa cDNA, and the human growth hormone gene polyadenylation signal. Microinjected embryos were transferred into pseudopregnant CDl females (Charles River Breeding Laboratories, Inc., Wilmington, MA) under Avertine anesthesia (0.38 g/kg body wt 2,2,2-tribromoethyl alcohol; Aldrich Chemical Company, Milwaukee, WI). Where indicated, the metallothionein promoter of the transgene was induced to maximum activity by maintaining mice on drinking water containing 50 mM zinc sulfate. All mice used in this study were cared for and maintained in accordance with guidelines set forth by the National Institutes of Health. Animals that became moribund or appeared in acute distress were euthanized.
Analysis ofgastricjuice. Routinely, gastric juice was obtained from mice that were starved for 24 h. The pylorus was ligated under methoxyflurane (Metofane; Pitman-Moore, Inc., Mundelein, IL) anesthesia. After -2.5 h without food or water, adult mice were again anesthetized and all fluid was removed from the stomachs. Because the stomachs of juvenile mice contained smaller amounts of juice, 0.25 ml saline was injected into the juvenile stomach and removed after 5 min. The pH of gastric juice was determined using a semi-micro combination pH electrode (Orion Research, Inc., Cambridge, MA). In some experiments, 500 ag/kg body wt ofpentagastrin (Sigma Chemical Co., St. Louis, MO) was injected subcutaneously 3 h after gastric ligation to stimulate acid secretion. 1 h after pentagastrin injection, mice were killed and the acid content of their stomachs was determined by titration with sodium hydroxide.
RNA analysis. Total tissue RNA was isolated and analyzed using Northern blot hybridization, as previously described ( 16, 22 4-* Study includes male and female mice. All animals were starved overnight. In adult mice (>3 mo old), gastric juice was removed directly from the stomach; in juvenile mice (< 1.5 mo old), juice was recovered after injection of saline into the stomach (see Methods). n, number of mice in which pH of stomach juice was examined. Average age of mice is given in months±SD. pH units are given±SD.
Immunohistochemistry. Mouse tissues were fixed in Bouin's solution, paraffin embedded, and sectioned. Immunohistochemistry was performed using standard techniques, except that deparaffinized sections were treated with 0.05% saponin for 2 h and 0.1% trypsin for 10-15 min at room temperature. TGFa was localized using rabbit polyclonal antiserum against a rat pro-TGFa intracellular peptide (residues 137-159) (23). Antibody was diluted up to 1:20,000 and incubated for 1 h at room temperature. Horseradish peroxidase staining was achieved using the ABC mouse IgG elite kit (Vector Laboratories, Burlingame, CA). Tissues to be processed only for routine histologic analysis were fixed in 10% buffered formalin and stained with hematoxylin and eosin (H&E).
Results
Adult TGFa transgenic mice from line MT 100, where stomach lesions were most severe, all developed age-dependent symptoms of malnutrition. The body wt of transgenic animals > 5 mo old was 25-33% less than controls, although food intake by TGFa and control mice was determined to be virtually identical. Heterozygous and homozygous MT100 mice died or were humanely killed by 10 and 6 mo of age, respectively. Gross morphologic analysis revealed that the glandular stomach was always firm and enlarged; the weight of the stomachs from the oldest MT100 mice was three to six times greater than nontransgenic controls. The gastric mucosa was extraordinarily thick (hypertrophic) with large nodular projections on the inside wall (Fig. 1, B and C) , while the lumen was severely constricted (Fig. 1 E) and contained viscous, mucous-laden secretions.
Histologic analysis revealed that hyperplastic changes were obvious in 31 of 31 MT100 mice between 1.5 and 10 mo ofage, compared to minimal or no changes in 15 of 15 FVB control mice (Fig. 1, G-I, and F, respectively) . 6-wk-old MT 100 mice exhibited small cysts and diffuse epithelial hyperplasia within the glandular portion of the gastric mucosa (Fig. 1 G) . By 6 mo, cystic hyperplasia was dramatic (Fig. 1 H) , but less severe in the antrum. The gastric mucosa was much enlarged, mainly because of hyperplasia of mucin-secreting columnar epithelia, as evidenced by the appearance of periodic acid Schiff (PAS) positive secretory material in cytoplasmic droplets of ductules and in many cysts (Fig. 1 J) . Microscopic analysis of thin sections of the MT 100 gastric mucosa stained with Azure Eosin-Nocht suggested that parietal cells were frequently compressed and decreased in number, particularly around or under cysts (data not shown). In addition, inflammatory cell infiltration and diffuse edema of the submucosa were evident. The gastric mucosa of mice surviving 8-10 mo of age grew increasingly thick and cystic, and contained foci of dysplastic cells possessing enlarged basophilic nuclei with abnormal polarity, and pseudostratification (Fig. 1, I and K). Hyperplastic secretory epithelium extended deep into the mucosa, and occasionally penetrated the submucosal layer to form diverticuli (Fig. 1 J) .
To determine if the transgenic parietal cell population was functional and effectively secreting acid, gastric juice was collected from the stomachs of MT100 and control mice. The pH of gastric juice from MT100 transgenic mice > 3 mo old was neutral or even slightly basic, strongly suggesting that parietal cell function was impaired in MT100 mice (Table I, Adult). This hypothesis was strengthened by measuring titratable gastric acid in untreated and pentagastrin-stimulated mice; the gastric juice in MT100 transgenic mice contained no detectable titratable acid, regardless of pentagastrin administration. Interestingly, the pH of gastric juice obtained from MT100 mice < 6 wk of age was not significantly different from nontransgenic controls (Table I, Juvenile) .
TGFa transgene expression in the stomach ofMT 100 mice was demonstrated using Northern blot analysis. Fig. 2 5 (B and C), 6 (E and H), 8 TGFa RNA transcripts. This pattern is typical for the mouse metallothionein I promoter, and similar, but not identical to, expression in MT42 TGFa transgenic mice described previously ( 16) . The stomachs ofjuvenile MT100 mice contained levels ofTGFa RNA comparable to adult transgenic mice (Fig.  2 B) . To localize transgene expression within the stomach, immunohistochemical staining was performed using an antibody specific for the intracellular portion ofthe proTGFa cellsurface precursor peptide (23). Fig. 3 A shows that TGFaspecific staining was strongest in glandular cells at the base of the crypts. However, when metallothionein-stimulating zinc water was ingested, surface mucous cells bordering the gastric lumen were induced to express high levels of TGFa as well (Fig. 3 B) .
The phenotypic consequences of overexpressing TGFa in the stomach varied in different transgenic lines. MT42 transgenic mice, derived from the outbred strain CD1, also exhibited cystic hyperplasia of the stomach; however, the disease developed slowly and was not associated with cachexia or parietal cell atrophy. Northern blot analysis revealed that transgene expression was not appreciably different in the stomachs of MT100 and MT42 mice (Fig. 2 B) . This finding suggests that the effect ofenhanced TGFa production on the gastric mucosa is strongly influenced by the genetic background upon which the transgene operates. The 10-mo-old transgenic progeny of a cross between MT100 and CD1 mice exhibited no signs of cachexia, and their stomachs contained variable but consistently less severe hypertrophic lesions (Figure 4 , B and C).
Discussion
Gastric lesions in TGFa transgenic mice grossly and microscopically resemble those seen in patients suffering from a rare disease originally described by Menetrier (20) . The nodular projections observed in the stomachs of MT100 mice are overtly analogous to the prominent giant rugal folds found in Menetrier's disease (20, 21 ) . As in MT100 mice, patients with Menetrier's disease exhibit mild to extraordinary cachexia, and their stomachs are characterized by cystic hyperplasia of mucous-secreting cells that spares the antrum, lymphocytic infiltrations, and parietal cell atrophy (24) (25) (26) . Moreover, in Menetrier's disease, the latter often results in a diminution or cessation of gastric acid production (21, 26, 27) ; this was consistently observed in adult MT100 mice as well.
Our data suggest that lesions resembling Menetrier's disease in these transgenic mice were caused by local overexpression of TGFa, and autocrine and/or paracrine stimulation of the EGF receptor. This hypothesis is further supported by the finding that gastric disease was consistently more severe in homozygous transgenic mice, capable of generating twice the amount ofTGFa. Furthermore, TGFa has been reported to be elevated in the gastric mucosa of Menetrier's patients (28 Variations in the development ofgastric lesions in different lines of TGFa transgenic mice and in the progeny of crosses between MT 100 and CD 1 mice suggest that the consequences ofTGFa overproduction were greatly influenced by the genetic background upon which the transgene operates. Our findings from this transgenic mouse model raise the possibility that the appearance of Menetrier's disease and the extent to which it develops in humans is likewise dependent on individual genetic makeup.
Menetrier's disease is considered by many to be a premalignant condition because 15% of reported cases included gastric carcinoma (26) . Furthermore, gastric cancer has been associated with overexpression of TGFa (29) . Although no TGFa transgenic mice developed gastric cancer, 5 of 12 MT100 animals > 8 mo of age possessed dysplastic foci within a background of severe adenomatous hyperplasia. Humans with such dysplastic lesions are at a higher risk of developing stomach cancer (24). Unfortunately, it has been difficult to assess the malignant potential of the gastric lesions in MT100 mice because of their abbreviated life span.
The MT 100 TGFa transgenic mouse appears to be an excellent animal model for Menetrier's disease. The rarity of Menetrier's disease and the dearth ofgood animal models have severely handicapped attempts to elucidate the pathophysiological nature of this syndrome. By permitting a detailed analysis ofthe pathogenesis ofthis hypertrophic gastropathy, our TGFa transgenic mouse model may shed light on the cause and treatment of Menetrier's disease and related human stomach disorders.
